In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Ean L SmallCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Shirley M SunCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0009-0007-6764-5750 Omkar ShindeCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Ram PantulaCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Photis RotsidesCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0003-2985-9954 Haotian DuDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Yi SunCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Daniel HwangCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-6071-8271 Chloe S WangCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Eli LaskawyCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Richa KapoorDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-4183-1332 Muzamil Y WantDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-9675-8910 Carl H JuneCenter for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0241-3557 Regina M YoungCenter for Cellular Immunotherapies of the University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-0158-9449 John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-8088-7929 Nikolaos G SgourakisCenter for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0003-3655-3902 Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MDiscovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7MAn integrative structural biology approach to understanding metabolite recognition by cellular receptorsR35GM125034 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SGOURAKIS, NIKOLAOS · 2017 to 2025
$4.7MNextGen - CHOPOT2CA278687 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2022 to 2026
$2.7MGenerative neural networks for structure-based antibody designR01GM147893 · NIGMS · STANFORD UNIVERSITY · PI Possu Huang · 2022 to 2026
$1.9MNCI NIH HHS OT2 CA278687NCI NIH HHS P30 CA016520NCI NIH HHS R35 CA220500NCI NIH HHS T32 CA009140NIAID NIH HHS P30 AI045008NIGMS NIH HHS R01 GM147893NIGMS NIH HHS R35 GM125034
6 · The paper itselfAbstract
T cell receptors (TCRs) and TCR-mimicking antibodies recognize peptide antigens in the context of specific Human Leucocyte Antigen (HLA-I) allotypes, and the extreme polymorphism of the HLA locus limits the breadth of immunotherapy development. Key barriers include divergent molecular surfaces on HLA proteins and differences in the peptide structure. As a result, existing modalities cannot confer therapeutic coverage across patients of divergent genetic backgrounds. Here, we develop an approach which combines a peptide conformational prediction tool, PepPred, with a cross-HLA binding protein engineering system, TRACeR-I
Identifiers
PMID42239416
PMCPMC13228281
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390